<DOC>
	<DOCNO>NCT00610961</DOCNO>
	<brief_summary>The increase immunosuppression transplant population lead unacceptable rate patient risk BK virus nephropathy . Reducing induction immunosuppression switch Thymoglobulin Simulect reduce incidence serum positivity BK PCR .</brief_summary>
	<brief_title>Induction Related BK Viremia Renal Transplant Patients</brief_title>
	<detailed_description>Our standard care change Thymoglobulin Simulect patient enrol observational trial gather data outcomes related BK viremia rejection rate . Two group patient compare . Retrospective ( historical control ) group subject : patient receive kidney transplant induct Thymoglobulin prior study initiation . Prospective group subject : patient schedule receive kidney transplant induct Simulect ( Basiliximab ) . Inductions group was/is Standard Care time treatment .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<criteria>De novo transplant Aged 1875 Serious medical condition , opinion Principal Investigator , might interfere subject 's ability successfully complete protocol . Any medical condition , opinion Principal Investigator , might compromise safety subject participate protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>BK Polyomavirus</keyword>
	<keyword>Transplantation , Kidney</keyword>
	<keyword>Transplantation , Pancreas</keyword>
</DOC>